Your browser doesn't support javascript.
loading
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
Landgren, C Ola; Chari, Ajai; Cohen, Yael C; Spencer, Andrew; Voorhees, Peter; Estell, Jane A; Sandhu, Irwindeep; Jenner, Matthew W; Williams, Catherine; Cavo, Michele; van de Donk, Niels W C J; Beksac, Meral; Moreau, Philippe; Goldschmidt, Hartmut; Kuppens, Steven; Bandekar, Rajesh; Clemens, Pamela L; Neff, Tobias; Heuck, Christoph; Qi, Ming; Hofmeister, Craig C.
Afiliação
  • Landgren CO; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. landgrec@mskcc.org.
  • Chari A; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Cohen YC; Department of Hematology, Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Spencer A; Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia.
  • Voorhees P; Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
  • Estell JA; Haematology Department, Concord Cancer Centre, Concord Hospital, University of Sydney, Concord, NSW, Australia.
  • Sandhu I; Department of Medicine, University of Alberta, Edmonton, AB, Canada.
  • Jenner MW; Southampton General Hospital, Southampton, UK.
  • Williams C; Department of Clinical Haematology, Nottingham University Hospitals, Nottinghamshire, UK.
  • Cavo M; Department of Experimental, Diagnostic and Specialty Medicine, "Seràgnoli" Institute of Hematology, University of Bologna, Bologna, Italy.
  • van de Donk NWCJ; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
  • Beksac M; Department of Hematology, Ankara University, Ankara, Turkey.
  • Moreau P; University Hospital Hôtel-Dieu, Nantes, France.
  • Goldschmidt H; University Hospital Heidelberg and National Center of Tumor Diseases (NCT), Heidelberg, Germany.
  • Kuppens S; Janssen Research & Development, Beerse, Belgium.
  • Bandekar R; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Clemens PL; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Neff T; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Heuck C; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Qi M; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Hofmeister CC; Department of Hematology & Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA. Craig.Hofmeister@emory.edu.
Leukemia ; 34(7): 1840-1852, 2020 07.
Article em En | MEDLINE | ID: mdl-32024950
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Latente / Anticorpos Monoclonais / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Latente / Anticorpos Monoclonais / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article